Ustekinumab 130mg/26ml solution for infusion vials
NHS hospitals in England used £67,045,690 of indicative cost of Ustekinumab 130mg/26ml solution for infusion vials in the 12 months to July 2026, about 0.3% of all hospital medicines spend. That is up 42.8% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Ustekinumab 130mg/26ml solution for infusion vials: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to July 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Ustekinumab 130mg/26ml solution for infusion vials most
By indicative cost over the 12 months to July 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| Salford Royal Nhs Foundation Trust | £1,900,095 |
| Oxford University Hospitals Nhs Ft | £1,857,155 |
| Western Sussex Hospitals Nhs Found Trust | £1,762,687 |
| Guy's & St Thomas' Nhs Foundation Trust | £1,715,453 |
| Manchester University Nhs Ft | £1,644,602 |
| University College London Foundation Tr | £1,629,573 |
| University Hpls Of Leicester Nhs Trust | £1,603,809 |
| Univ Hpl B/Ham Nhs Foundation Trust | £1,425,608 |
| University Hospital Southampton Nhs Ft | £1,417,020 |
| Royal Devon & Exeter Nhs Foundation Trst | £1,296,788 |
The primary-care picture
Ustekinumab is also dispensed in the community. See the national primary-care prescribing volume, cost and trend on the Ustekinumab medicine page.